Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of βIII-Tubulin Expression as a Predictive Marker

BACKGROUND. This randomized phase II trial was designed to compare the rate of pathologic complete response (pCR) induced by neoadjuvant cyclophosphamide plus doxorubicin (AC) followed by ixabepilone or paclitaxel in women with early stage breast cancer (BC). Expression of βIII-tubulin as a predicti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Saura, Cristina, Tseng, Ling-Ming, Chan, Stephen, Chacko, Raju T., Campone, Mario, Manikhas, Alexy, Nag, Shona M., Leichman, Cynthia G., Dasappa, Lokanatha, Fasching, Peter A., Hurtado de Mendoza, Fernando, Symmans, W. Fraser, Liu, David, Mukhopadhyay, Pralay, Horak, Christine, Xing, Guan, Pusztai, Lajos
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2013
Soggetti:
Academia-Pharma Intersect: Breast Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3720631/
https://ncbi.nlm.nih.gov/pubmed/23853246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0075
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi